The recent purchase by Sergio Traversa indicates optimism about the company's future. Despite the company making losses, the insider transactions suggest confidence in a bright future for Relmada Therapeutics.
$SPDR標普生物科技ETF(XBI.US)$ The biotech sector faced challenges in the previous year, mainly attributed to high inflation and interest rates, particularly impacting small-cap biotech firms in the difficult fundraising environment of summer 2023. As a consequence, numerous companies experienced a significant drop in their market caps, with some even falling below the 100 million mark, a rarity...
Relmada Therapeutics股票討論區
The biotech sector faced challenges in the previous year, mainly attributed to high inflation and interest rates, particularly impacting small-cap biotech firms in the difficult fundraising environment of summer 2023.
As a consequence, numerous companies experienced a significant drop in their market caps, with some even falling below the 100 million mark, a rarity...
$ACM Research(ACMR.US)$ $Applied DNA Sciences(APDN.US)$ $Corbus Pharmaceuticals(CRBP.US)$ $Digital World Acquisition Corp(DWAC.US)$ $FedNat(FNHC.US)$ $IMARA(IMRA.US)$ $Laser Photonics(LASE.US)$ $新紀元能源(NEE.US)$ $Relmada Therapeutics(RLMD.US)$ $Senti Biosciences(SNTI.US)$ $Visa(V.US)$ $SPDR金融行業ETF(XLF.US)$
暫無評論